ArticleAnnals of oncology : official journal of the European Society for Medical Oncology2014
Effects of newly developed chemotherapy regimens, comorbidities, chemotherapy-related toxicities on the changing patterns of the leading causes of death in elderly patients with colorectal cancer.
Article in Annals of oncology : official journal of the European Society for Medical Oncology, 2014. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 16 papers.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
16 citing papers in PubMed, 46 citations in OpenAlex.
- Treatment patterns, and outcomes in elderly patients with metastatic non-small cell lung cancer: a real-world analysis from a single center in China.BMC geriatrics · 2026Article
- Comparative Analysis of Speckle-tracking Echocardiography and Cardio-specific Markers for Early Detection of Cardiotoxicity in Patients With Breast Cancer.Journal of the Saudi Heart Association · 2025Article
- A Prognostic Model Based on the Log Odds Ratio of Positive Lymph Nodes Predicts Prognosis of Patients with Rectal Cancer.Journal of gastrointestinal cancer · 2024Article
- Synthesis of compounds based on the active domain of cabotegravir and their application in inhibiting tumor cells activity.ChemistryOpen · 2024Article
- Elderly patients with stage II gastric cancer do not benefit from adjuvant chemotherapy.World journal of surgical oncology · 2023Article
- Impact of Patient Comorbidities on Presentation Stage of Breast and Colon Cancers.Annals of surgical oncology · 2023Article
- Associations of advanced age with comorbidity, stage and primary subsite as contributors to mortality from colorectal cancer.Frontiers in public health · 2023Article
- Causes of death among early-onset colorectal cancer population in the United States: a large population-based study.Frontiers in oncology · 2023Article
- Causes of Death Following Nonmetastatic Colorectal Cancer Diagnosis in the U.S.: A Population-Based Analysis.The oncologist · 2021Article
- Analyzing non-cancer causes of death of colorectal carcinoma patients in the US population for the years 2000-2016.Cancer medicine · 2021Article
- Estimating Chemotherapy Use Among Patients With a Prior Primary Cancer Diagnosis Using SEER-Medicare Data.Journal of the National Cancer Institute. Monographs · 2020Article
- Therapeutic Characteristics, Chemotherapy-Related Toxicities and Survivorship in Colorectal Cancer Patients.Ethiopian journal of health sciences · 2020Article
- Adjuvant chemotherapy does not provide survival benefits to elderly patients with stage II colon cancer.Scientific reports · 2019Article
- Colon cancer survival in the United States by race and stage (2001-2009): Findings from the CONCORD-2 study.Cancer · 2017Article
- CENPH Inhibits Rapamycin Sensitivity by Regulating GOLPH3-dependent mTOR Signaling Pathway in Colorectal Cancer.Journal of Cancer · 2017Article
- Impact of age and comorbidity on survival in colorectal cancer.Journal of gastrointestinal oncology · 2015Article
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
5 authors at 4 institutions in 1 country.
Funding
Abstract
backgroundAbundant evidences have shown that newly developed chemotherapy regimens improved 5-year survival rate of colorectal cancer (CRC) patients over the past two decades. However, their impact on risk of death from leading causes among elderly patients is still poorly understood. PATIENTS AND
methodsA retrospective cohort study of 69 718 elderly CRC patients with their first primary tumors in 1992-2009, identified from the 12 areas of Surveillance, Epidemiology, and End Results-Medicare linked database with their Medicare claims up to 2010. Multivariate Cox regression models were used to assess the effect of newly developed chemotherapy regimens, comorbidities, and chemotherapy related toxicities on cause-specific death and their temporal patterns among elderly CRC patients.
resultsThe leading causes of death among CRC patients were CRC, circulation disorders, and secondary cancers, which accounted for 51.4%, 25%, and 4.6% of all-cause death, respectively. Patients diagnosed in more recent diagnostic time periods were significantly less likely to die of CRC [period 2: 5-year hazard ratio = 0.94, 95% confidence interval (CI) 0.90-0.97; period 3: 0.86, 0.83-0.90], circulation disorders (period 2: 0.94, 0.88-1.00; period 3: 0.80, 0.75-0.87), and more likely to die of secondary cancer (period 3: 1.42, 1.20-1.68) compared with those diagnosed in period 1. Charlson comorbidities index and the selected pre-existing comorbidities were significantly associated with increased 5-year risk of death from all three leading causes. Both hematological and gastric toxicity were associated with reduced risk of death from CRC and circulation disorders. The association between diagnostic time period and risk reduction in death from CRC depended on chemotherapy treatment (P < 0.0001). Subgroup analyses showed that the chemotherapy-dependent significant risk reduction was seen in patients with stage II-III CRC, patients without comorbidities, and patients without toxicities (P < 0.0001 for all).
conclusionThe newly developed chemotherapy regimens were associated with the decreased risk of mortality from CRC.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.